[link to clinicaltrials.gov (secure)]
Prophylaxis Covid-19 in Healthcare Agents by Intensive Treatment With Ivermectin and Iota-carrageenan (Ivercar-Tuc)

NB: Ivermectin stops virus replication and transmission, so will stop mutations dead.

RESULT: The number of subjects who were diagnosed with COVID-19 in the Experimental Group (EG) was lower, only 4 of 117 (3.4%) than subjects in the Control Group (CG): 25 of 117 (21.4%) (p-Value = 0.0001).
Twenty patients had mild symptoms (Experimental group: n=4, Control Group: n=16).
Six subjects were moderate, and 3 with severe diagnostics, all of them in the CG (no Ivermectin).